Post Tagged with: "sativex"

Three Pots Stocks To Watch Out For, According to NASDAQ

Three Pots Stocks To Watch Out For, According to NASDAQ

Although the company isn’t yet profitable, GW claims some financial positives that most other marijuana stocks can’t. Thanks to Sativex, it has a solid revenue stream, generating over $46 million in the last 12 months. The company’s cash position also looks pretty good, with $234 million in cash and cash equivalents. 2. Insys Therapeutics Insys Therapeutics’ financial position looks even […]

July 12, 2015 · 0 comments · Feature Article
2015’s Top Marijuana Stocks To Watch Out For

2015’s Top Marijuana Stocks To Watch Out For

          Market leader GW Pharmaceuticals (GWPH) started to come back from a sell-off period in late December. Anticipator buying prior to GW’s Sativex results saw the stock rise from $67 to highs of $80.68. Unfortunately for the company and the stock as of recent weeks, results were dismal. Also looking to benefit from patent filing is […]

June 19, 2015 · 0 comments · Feature Article
What The Public Should Know About Marijuana Stocks For 2015

What The Public Should Know About Marijuana Stocks For 2015

But when you look at their price to sales, for example, for the trailing 12 months, it’s 33 according to Yahoo! Finance. That is a pretty substantial … that’s priced to perfection, and I think that there are a couple of concerns there. For me, one of the big ones is there’s an election that says, “We’re legalizing marijuana in […]

January 21, 2015 · 0 comments · Feature Article
Can This Year Be A Good Year For Marijuana Stocks?

Can This Year Be A Good Year For Marijuana Stocks?

The company plans to announce phase 3 results from its first cancer study early next year, with results from a second phase 3 study expected in the second quarter. If those results are positive, GW Pharma hopes to file for FDA approval in the second half of next year; with the agency’s OK, Sativex could reach the U.S. market in […]

January 5, 2015 · 0 comments · Feature Article
Cannagrow Holdings, Inc. Puts Itself As A Leader In Expanding Cannabis Industry In Colorado

Cannagrow Holdings, Inc. Puts Itself As A Leader In Expanding Cannabis Industry In Colorado

Legalization amendments in Oregon , Alaska, and Washington D.C. all passed, allowing for the taxation and regulation of marijuana, and hence its legal sale; but even ballot measures that failed still made waves, such as Amendment 2 in largely conservative Florida , which would have granted the right to the use of medical marijuana and only failed by a miniscule […]

November 13, 2014 · 0 comments · Feature Article
What’s The New GW Pharma?

What’s The New GW Pharma?

Cannabis Technologies trades at $0.37 is pre-revenue and has a market cap of $12 million with roughly $600k in cash. CAN shares have a 2014 high of $0.71 and low of $0.33. GWPH market cap is 30 times revenue. Translating that multiple to eventual revenues to early stage CAN evidences compelling growth potential. GWPH, as CAN, decided early on to […]

October 16, 2014 · 0 comments · Feature Article
Another Marijuana Stock Showdown: GW Pharmaceuticals vs. Medbox

Another Marijuana Stock Showdown: GW Pharmaceuticals vs. Medbox

GW Pharma’s Sativex is in late-stage trials as a potential treatment for pain in patients with advanced forms of cancer, with the FDA granting the drug fast-track status for this indication earlier this year. The company hopes to report top-line data from the trial before the end of 2014. GW also sees potential in its highly purified cannabinoid known as […]

September 19, 2014 · 0 comments · Feature Article
CBD Hemp Oil Product Potential Continues To Flourish

CBD Hemp Oil Product Potential Continues To Flourish

Cannabidiol (“CBD”) is one of at least 60 active cannabinoids identified in both cannabis and industrial hemp. It is present in both plants although the prevalence or total composition of CBD can vary greatly from strain to strain. GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. […]

August 13, 2014 · 0 comments · Feature Article
Cramer Doubtful Regarding Investing In Marijuana Stock Overseas

Cramer Doubtful Regarding Investing In Marijuana Stock Overseas

Instead, this U.K.-based company is at the forefront of developing new drugs from compounds found in cannabis, or marijuana plants. “And I think few doctors want to write anyone a prescription for a joint, not just because the stuff is still illegal where the Federal government’s concerned, but mostly because, while smoking weed may help people who have cancer or […]

June 29, 2014 · 0 comments · Feature Article
This Medical Pot Stock Is Not What You Think It Is

This Medical Pot Stock Is Not What You Think It Is

And there’s risk that the company won’t get Sativex approved or that it won’t sell well if clinical trials show that it’s not better than generic pain medications. I like the risk-reward situation here, at a market cap under $700 million, than I did when the company was over $1.2 billion, but only for an investor that’s willing to hold […]

June 20, 2014 · 0 comments · Feature Article